Hotgen(SH:688068) Ge Long Hui A P P·2025-08-13 09:05Core Viewpoint - The company, Hotgen Biotech (688068.SH), has approved a capital increase for its associate company, Shunjing Pharmaceutical, through a board meeting held on August 12, 2025, involving a total investment of 100 million yuan [1] Group 1: Capital Increase Details - The capital increase will be priced at 25 yuan per registered capital, raising Shunjing Pharmaceutical's registered capital from 72 million yuan to 76 million yuan [1] - After the capital increase, the company's equity stake in Shunjing Pharmaceutical will decrease from 45.5833% to 43.1842% [1] - The company has decided to waive its preferential subscription rights for this capital increase [1] Group 2: Related Party Transactions - Shunjing Pharmaceutical is an associate company in which the company holds a 45.5833% stake [1] - Lin Changqing, the company's controlling shareholder and actual controller, is also the legal representative and chairman of Shunjing Pharmaceutical, indicating a related party relationship [1] - The company's decision to waive its preferential subscription rights constitutes a related party transaction under the Shanghai Stock Exchange's regulations [1]